VSIG2: V-Set and Immunoglobulin Domain Containing 2
A transmembrane protein with roles in cell adhesion and potential implications in cancer and immune regulation.
Gene Information Card
| Symbol | VSIG2 |
|---|---|
| Full Name | V-Set and Immunoglobulin Domain Containing 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 11q24.2 |
| NCBI Gene ID | 23584 ncbi.nlm.nih.gov/gene/23584 |
| Ensembl ID | ENSG00000149476 |
| UniProt ID | Q96IQ7 |
| OMIM ID | 617190 |
| HGNC ID | 20236 |
| Aliases | CTH, CTH1, IgSF, VSIG2 |
Description
VSIG2 (V-Set and Immunoglobulin Domain Containing 2) is a protein-coding gene located on chromosome 11q24.2. It encodes a transmembrane protein belonging to the immunoglobulin superfamily, characterized by V-set and immunoglobulin domains. VSIG2 is involved in cell-cell adhesion and may play roles in immune modulation and tumor biology. Expression is enriched in epithelial tissues, and alterations have been reported in various cancers.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal Cancer | Downregulation of VSIG2 may promote tumor progression and metastasis through altered cell adhesion. | PMID: 25944712 |
| Gastric Cancer | Reduced VSIG2 expression correlates with poor prognosis and increased invasiveness. | PMID: 27121310 |
| Lung Cancer | VSIG2 hypermethylation and silencing observed in non-small cell lung cancer. | COSMIC, PMID: 24120480 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lung | 12.5 | Medium |
| Stomach | 10.3 | Medium |
| Colon | 8.7 | Medium |
| Kidney | 6.2 | Low |
| Liver | 2.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| A549 (lung carcinoma) | 15.4 | High expression |
| MCF7 (breast cancer) | 4.3 | Low expression |
| HCT116 (colorectal carcinoma) | 9.8 | Medium expression |
| HEK293 (embryonic kidney) | 1.2 | Very low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.487C>T (p.Arg163Trp) | Missense | 0.02% | Unknown functional impact |
| c.1021G>A (p.Gly341Arg) | Missense | 0.01% | Predicted damaging (SIFT) |
| c.1245_1246insA | Frameshift | <0.01% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations likely lead to loss of VSIG2 protein function, potentially contributing to tumor progression.
Gain of Function (GOF)
No gain-of-function mutations reported in VSIG2.
Dominant Negative (DN)
No dominant-negative mutations described for VSIG2.
View complete mutation data：
Gene Ontology (GO)
| • cell adhesion (GO:0007155) | • plasma membrane (GO:0005886) |
| • protein binding (GO:0005515) | • integral component of membrane (GO:0016021) |
Pathways
• Cell adhesion molecules (CAMs) - Homo sapiens (hsa04514)
• Immunoglobulin superfamily signaling
Protein Summary
VSIG2 encodes a type I transmembrane glycoprotein with two extracellular immunoglobulin-like domains (V-set and C2-set). It is expressed on epithelial cells and mediates homophilic cell-cell adhesion. The protein may function as a tumor suppressor in certain cancers, with loss of expression linked to metastasis and poor prognosis. Its role in immune modulation is under investigation.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| VSIG2 Knockout HEK293 Cell Line | EDJ-KQ7405 | Human | 23584 | Details Get a Quote |
| VSIG2 Knockout HeLa Cell Line | EDJ-KQ55777 | Human | 23584 | Details Get a Quote |
| VSIG2 Knockout A-549 Cell Line | EDJ-KQ64272 | Human | 23584 | Details Get a Quote |
| VSIG2 Knockout HCT 116 Cell Line | EDJ-KQ72718 | Human | 23584 | Details Get a Quote |
